Robust prognostic model based on immune infiltration‐related genes and clinical information in ovarian cancer

Xi Zhang, Weikaixin Kong, Miaomiao Gao, Weiran Huang, Chao Peng, Zhuo Huang, Zhengwei Xie, Hongyan GuoJournal of Cellular and Molecular Medicine 2022 · DOI

TL;DR

This study develops a robust prognostic model (IGCI score) for ovarian cancer by integrating immune infiltration-related genes and clinical information. The IGCI score significantly outperforms existing staging systems in predicting patient survival and offers a more personalized approach to treatment by identifying key gene mutations that influence drug sensitivity.

What Problem Does This Paper Address?

Ovarian cancer (OV) is a highly lethal gynecological malignancy, with a poor 5-year survival rate, largely due to late-stage diagnosis and frequent recurrence. While immune infiltration is known to be a critical factor in patient prognosis, effectively leveraging this information for clinical decision-making has been challenging. Existing prognostic models, like the AJCC stage, often lack the granularity to capture the complex interplay between the tumor microenvironment and patient outcomes. This paper aims to address this gap by developing a more accurate and personalized prognostic tool that incorporates immune-related genetic markers and clinical data.

Methods

The researchers employed a multi-faceted bioinformatic approach. They began by identifying differentially expressed genes (DEGs) between cancerous and normal ovarian tissues using data from TCGA and GTEx. To understand the immune microenvironment, they utilized the ESTIMATE algorithm to calculate immune and stromal scores, identifying DEGs associated with these scores. Weighted Gene Correlation Network Analysis (WGCNA) was then applied to identify key gene modules and hub genes related to OV development and immune infiltration.

A crucial step was the integration of these findings. They identified 46 genes that were common to both the WGCNA hub genes and the DEGs related to immune infiltration. These 46 genes, along with 7 clinical factors, were then subjected to Lasso regression to select the most predictive features. Finally, a multivariate Cox proportional hazards regression model was built to establish the Immune-related Gene and Clinical Information (IGCI) score. This score was validated using Kaplan-Meier curves, ROC curves, and C-indices on independent training and test sets. Additionally, the study investigated the prognostic significance of gene mutations using chi-squared tests and survival analysis, and explored the impact of key mutations on drug sensitivity using data from the Genomics of Drug Sensitivity in Cancer (GDSC) database.

Datasets

  • The Cancer Genome Atlas (TCGA): Used for RNA sequencing data (379 ovarian cancer samples) and SNP data (436 ovarian cancer samples). Also used for mRNA and clinical information for 258 tumor samples.
  • Genotype-Tissue Expression (GTEx) database: Used for RNA sequencing data of 88 normal ovarian tissues.
  • Genomics of Drug Sensitivity in Cancer (GDSC) database: Used for drug sensitivity analysis of key gene mutations.
  • Human Protein Atlas database: Used for immunohistochemistry (IHC) datasets to explore protein levels of key genes.

Key Insights and Ideas

  • Immune infiltration is a powerful prognostic indicator: The study strongly reinforces the idea that the tumor's immune microenvironment is not just a bystander but a critical determinant of ovarian cancer patient outcomes.
  • Integration is key: Combining gene expression data related to immune infiltration with standard clinical information yields a more accurate prognostic tool than either alone.
  • Specific genes hold prognostic power: The identification of FGF7, CCR1, and CD14 as key components of the IGCI score highlights specific molecular players that can be targeted for better prediction and potentially therapy.
  • Mutations matter for prognosis and treatment: Certain gene mutations (e.g., RB1, CSMD3) are not only linked to patient prognosis but also significantly alter the sensitivity to specific anti-cancer drugs, paving the way for personalized treatment strategies.
  • RB1 mutation as a potential biomarker for drug response: The finding that RB1 mutations alter the efficacy of several drugs suggests a potential for genotype-guided drug selection in ovarian cancer.

Key Results

  • Identification of 46 immune infiltration-related genes: These genes were identified through the integration of WGCNA and ESTIMATE methods.
  • Development of the IGCI score: This score is based on 3 immune genes (FGF7, CCR1, CD14) and 3 clinical factors (Age, White race, Pharmaceutical Therapy).
  • Superior predictive performance: The IGCI score achieved a C-index of 0.630 in the test set, which was significantly better than the AJCC stage (C-index = 0.541) and CIN25 (C-index = 0.571).
  • Nomogram validation: A nomogram based on the IGCI score was developed and validated, demonstrating good predictive accuracy for 1-, 3-, and 5-year survival rates with AUCs in the test set reaching up to 0.766.
  • Identification of prognostic mutations: Five key mutations (CSMD3, FLG2, HMCN1, TOP2A, TRRAP) were found to be significantly related to patient prognosis.
  • Drug sensitivity alterations: RB1 mutations were associated with significant changes in the efficacy of six anti-tumor drugs.

Limitations and Future Work

  • Retrospective study design: The study relies on existing datasets (TCGA, GTEx), which are retrospective. Prospective validation in larger, diverse cohorts is necessary.
  • Limited clinical factors: While the IGCI score includes clinical factors, it acknowledges that other factors might also influence prognosis.
  • Mechanism of action: While key genes and mutations are identified, the precise biological mechanisms by which they influence immune infiltration and prognosis require further investigation.
  • Drug sensitivity complexity: The drug sensitivity analysis was based on a database and requires experimental validation in cell lines or animal models.
  • Future Directions: The authors suggest further studies to confirm the involvement of identified genes (e.g., RBAK) and their interactions, and to explore the potential of these findings for developing novel therapeutic strategies and biomarkers. The development of clinical tools based on the IGCI score is also a logical next step.

Summary updated

Abstract

Immune infiltration of ovarian cancer (OV) is a critical factor in determining patient's prognosis. Using data from TCGA and GTEx database combined with WGCNA and ESTIMATE methods, 46 genes related to OV occurrence and immune infiltration were identified. Lasso and multivariate Cox regression were applied to define a prognostic score (IGCI score) based on 3 immune genes and 3 types of clinical information. The IGCI score has been verified by K-M curves, ROC curves and C-index on test set. In test set, IGCI score (C-index = 0.630) is significantly better than AJCC stage (C-index = 0.541, p < 0.05) and CIN25 (C-index = 0.571, p < 0.05). In addition, we identified key mutations to analyse prognosis of patients and the process related to immunity. Chi-squared tests revealed that 6 mutations are significantly (p < 0.05) related to immune infiltration: BRCA1, ZNF462, VWF, RBAK, RB1 and ADGRV1. According to mutation survival analysis, we found 5 key mutations significantly related to patient prognosis (p < 0.05): CSMD3, FLG2, HMCN1, TOP2A and TRRAP. RB1 and CSMD3 mutations had small p-value (p < 0.1) in both chi-squared tests and survival analysis. The drug sensitivity analysis of key mutation showed when RB1 mutation occurs, the efficacy of six anti-tumour drugs has changed significantly (p < 0.05).
BibTeX
@article{zhang2022robust,
  author = {Xi Zhang and Weikaixin Kong and Miaomiao Gao and Weiran Huang and Chao Peng and Zhuo Huang and Zhengwei Xie and Hongyan Guo},
  title = {{Robust prognostic model based on immune infiltration‐related genes and clinical information in ovarian cancer}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2022},
  doi = {10.1111/jcmm.17360},
}
Figure